Results from a multicenter, noninterventional registry study
for multiple myeloma patients who received stem cell
mobilization regimens with and without plerixafor

J 2020

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

MORRIS, Curly; Christian CHABANNON; Tamas MASSZI; Nigel RUSSELL; Hareth NAHI et al.

Základní údaje

Originální název

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Autoři

Vydání

Bone Marrow Transplantation, London, Nature Publishing Group, 2020, 0268-3369

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.483

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00115987

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

COLONY-STIMULATING FACTOR; AMERICAN SOCIETY; POOR MOBILIZATION; RISK-FACTORS; BLOOD; TRANSPLANTATION; GUIDELINES; OUTCOMES; CHEMOTHERAPY; COLLECTION

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 7. 2020 10:15, Mgr. Tereza Miškechová

Anotace

V originále

Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

Citovat

MORRIS, Curly; Christian CHABANNON; Tamas MASSZI; Nigel RUSSELL; Hareth NAHI; Guido KOBBE; Marta KREJČÍ; Holger W. AUNER; David POHLREICH; Patrick HAYDEN; Grzegorz W. BASAK; Stig LENHOFF; Nicolaas SCHAAP; Anja VAN BIEZEN; Cora KNOL; Simona IACOBELLI; Qianying LIU; Marina CELANOVIC; Laurent GARDERET a Nicolaus KROGER. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation. London: Nature Publishing Group, 2020, roč. 55, č. 2, s. 356-366. ISSN 0268-3369. Dostupné z: https://doi.org/10.1038/s41409-019-0676-0.

@article{1670357,
   author = {Morris, Curly and Chabannon, Christian and Masszi, Tamas and Russell, Nigel and Nahi, Hareth and Kobbe, Guido and Krejčí, Marta and Auner, Holger W. and Pohlreich, David and Hayden, Patrick and Basak, Grzegorz W. and Lenhoff, Stig and Schaap, Nicolaas and van Biezen, Anja and Knol, Cora and Iacobelli, Simona and Liu, Qianying and Celanovic, Marina and Garderet, Laurent and Kroger, Nicolaus},
   article_location = {London},
   article_number = {2},
   doi = {https://doi.org/10.1038/s41409-019-0676-0},
   keywords = {COLONY-STIMULATING FACTOR; AMERICAN SOCIETY; POOR MOBILIZATION; RISK-FACTORS; BLOOD; TRANSPLANTATION; GUIDELINES; OUTCOMES; CHEMOTHERAPY; COLLECTION},
   language = {eng},
   issn = {0268-3369},
   journal = {Bone Marrow Transplantation},
   title = {Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor},
   url = {https://www.nature.com/articles/s41409-019-0676-0.pdf},
   volume = {55},
   year = {2020}
}

TY  - JOUR
ID  - 1670357
AU  - Morris, Curly - Chabannon, Christian - Masszi, Tamas - Russell, Nigel - Nahi, Hareth - Kobbe, Guido - Krejčí, Marta - Auner, Holger W. - Pohlreich, David - Hayden, Patrick - Basak, Grzegorz W. - Lenhoff, Stig - Schaap, Nicolaas - van Biezen, Anja - Knol, Cora - Iacobelli, Simona - Liu, Qianying - Celanovic, Marina - Garderet, Laurent - Kroger, Nicolaus
PY  - 2020
TI  - Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
JF  - Bone Marrow Transplantation
VL  - 55
IS  - 2
SP  - 356-366
EP  - 356-366
PB  - Nature Publishing Group
SN  - 02683369
KW  - COLONY-STIMULATING FACTOR
KW  - AMERICAN SOCIETY
KW  - POOR MOBILIZATION
KW  - RISK-FACTORS
KW  - BLOOD
KW  - TRANSPLANTATION
KW  - GUIDELINES
KW  - OUTCOMES
KW  - CHEMOTHERAPY
KW  - COLLECTION
UR  - https://www.nature.com/articles/s41409-019-0676-0.pdf
L2  - https://www.nature.com/articles/s41409-019-0676-0.pdf
N2  - Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.
ER  -

MORRIS, Curly; Christian CHABANNON; Tamas MASSZI; Nigel RUSSELL; Hareth NAHI; Guido KOBBE; Marta KREJČÍ; Holger W. AUNER; David POHLREICH; Patrick HAYDEN; Grzegorz W. BASAK; Stig LENHOFF; Nicolaas SCHAAP; Anja VAN BIEZEN; Cora KNOL; Simona IACOBELLI; Qianying LIU; Marina CELANOVIC; Laurent GARDERET a Nicolaus KROGER. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. \textit{Bone Marrow Transplantation}. London: Nature Publishing Group, 2020, roč.~55, č.~2, s.~356-366. ISSN~0268-3369. Dostupné z: https://doi.org/10.1038/s41409-019-0676-0.

Přehled o publikaci